相似文献
1
Loracarbef concentrations in middle ear fluid.
Antimicrob Agents Chemother. 1990 Oct;34(10):2030-1. doi: 10.1128/AAC.34.10.2030.
2
Penetration of ceftibuten into middle ear fluid.
Antimicrob Agents Chemother. 1996 Jun;40(6):1394-6. doi: 10.1128/AAC.40.6.1394.
3
Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.
Paediatr Drugs. 2007;9(2):119-23. doi: 10.2165/00148581-200709020-00005.
4
Concentrations of antimicrobial agents in middle ear fluid, saliva and tears.
Int J Pediatr Otorhinolaryngol. 1981 Dec;3(4):327-34. doi: 10.1016/0165-5876(81)90057-4.
5
Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media.
J Infect Dis. 1982 Jun;145(6):815-21. doi: 10.1093/infdis/145.6.815.
6
Penetration of trimethoprim--sulfadiazine into middle ear fluid in secretory otitis media.
Int J Pediatr Otorhinolaryngol. 1983 Sep;6(1):89-94. doi: 10.1016/s0165-5876(83)80107-4.
7
Microdialysis studies of the distribution of antibiotics into chinchilla middle ear fluid.
Pharmacotherapy. 2005 Dec;25(12 Pt 2):140S-145S. doi: 10.1592/phco.2005.25.12part2.140S.
8
Pharmacokinetics of loracarbef in pediatric patients.
Eur J Drug Metab Pharmacokinet. 1992 Jul-Sep;17(3):201-4. doi: 10.1007/BF03190146.
9
Penetration of cefprozil into middle ear fluid of patients with otitis media.
Antimicrob Agents Chemother. 1994 Sep;38(9):2210-2. doi: 10.1128/AAC.38.9.2210.
10
Penetration of cefpodoxime into middle ear fluid in pediatric patients with acute otitis media.
Pediatr Infect Dis J. 1997 Jan;16(1):79-81. doi: 10.1097/00006454-199701000-00020.
引用本文的文献
1
In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance.
Antimicrob Agents Chemother. 1998 Aug;42(8):1973-9. doi: 10.1128/AAC.42.8.1973.
2
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.
Antimicrob Agents Chemother. 1996 May;40(5):1148-52. doi: 10.1128/AAC.40.5.1148.
3
Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.
Drugs. 1993 May;45(5):716-36. doi: 10.2165/00003495-199345050-00008.
4
Clinical pharmacokinetics of newer cephalosporins.
Clin Pharmacokinet. 1995 May;28(5):361-84. doi: 10.2165/00003088-199528050-00003.
5
Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams.
Antimicrob Agents Chemother. 1992 Mar;36(3):521-6. doi: 10.1128/AAC.36.3.521.
6
Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-1-dethiacephalosporin antibiotic.
Pharm Res. 1992 Feb;9(2):250-4. doi: 10.1023/a:1018949709797.
本文引用的文献
1
Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media.
J Infect Dis. 1982 Jun;145(6):815-21. doi: 10.1093/infdis/145.6.815.
2
Concentrations of antimicrobial agents in middle ear fluid, saliva and tears.
Int J Pediatr Otorhinolaryngol. 1981 Dec;3(4):327-34. doi: 10.1016/0165-5876(81)90057-4.
3
Pharmacokinetics of LY163892 in infants and children.
Antimicrob Agents Chemother. 1988 Nov;32(11):1738-9. doi: 10.1128/AAC.32.11.1738.
4
In vitro susceptibilities of common pediatric pathogens to LY163892.
Antimicrob Agents Chemother. 1988 Feb;32(2):268-70. doi: 10.1128/AAC.32.2.268.
Zotero 插件